Xeris Biopharma Holdings, Inc.XERS
What Xeris Biopharma Holdings, Inc. does.
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit.
We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
• Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. Endogenous Cushing’s syndrome is a rare but serious and potentially fatal endocrine disease caused by chronic elevated cortisol exposure. Recently published data has shown that hypercortisolemia may be a contributor to several widespread and chronic medical conditions suggesting that the prevalence of the condition may be significantly higher than previously believed. We believe this therapy represents a significant commercial opportunity in the United States, with the potential to generate approximately $1 billion in annual net revenue at peak penetration.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $20.4M | $49.6M | $110.2M | $163.9M | $203.1M | $291.8M |
| Net income | -$91.1M | -$122.7M | -$94.7M | -$62.3M | -$54.8M | $554,000 |
| Free cash flow | -$80.9M | -$96.6M | — | — | — | — |
More on XERS.
- Xeris Biopharma Holdings, Inc. summary
- Xeris Biopharma Holdings, Inc. financial statements
- Xeris Biopharma Holdings, Inc. key metrics
- Xeris Biopharma Holdings, Inc. health scores and style box
- Xeris Biopharma Holdings, Inc. earnings
- Xeris Biopharma Holdings, Inc. dividends
- Xeris Biopharma Holdings, Inc. valuation
- Xeris Biopharma Holdings, Inc. ownership and insiders
- Xeris Biopharma Holdings, Inc. peers
Figures from Xeris Biopharma Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.